source
- Westlake-backed Vedana Therapeutics raises $46M to develop anti-PACAP migraine prevention drugsVedana Therapeutics, a new biotech formed out of stealth, announced it has secured $46 million in financing backed by Westlake. The capital will be used to advance its anti-PACAP antibody program a…
- Neumora ends development of navacaprant after failed Phase 3 depression trials; EnGene cuts half its workforceNeumora Therapeutics announced it will discontinue its kappa opioid receptor antagonist navacaprant after the drug missed its primary endpoints in two Phase 3 studies for major depressive disorder.…